

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/16, 38/17, C07H 21/04, C12Q 1/08	A1	(11) International Publication Number: WO 97/33605 (43) International Publication Date: 18 September 1997 (18.09.97)
(21) International Application Number: PCT/US97/05809 (22) International Filing Date: 14 March 1997 (14.03.97) (30) Priority Data: 60/013,625 15 March 1996 (15.03.96) US (71) Applicant (for all designated States except US): YALE UNIVERSITY [US/US]; Yale Office of Cooperative Research, Suite 401, 246 Church Street, New Haven, CT 06510 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): ANDERSON, James, M. [US/US]; 84 Marvel Road, New Haven, CT 06515 (US). VAN ITALLIE, Christina, M. [US/US]; 84 Marvel Road, New Haven, CT 06510 (US). (74) Agent: KRINSKY, Mary, M.; St. Onge Steward Johnston & Reens L.L.C., 986 Bedford Street, Stamford, CT 06905-5619 (US).	(81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>	
(54) Title: HUMAN OCCLUDIN, ITS USES AND ENHANCEMENT OF DRUG ABSORPTION USING OCCLUDIN INHIBITORS (57) Abstract The gene for human occludin, an integral transmembrane protein specifically associated with tight junctions that functions in forming intercellular seals, is cloned, characterized, and sequenced, and the polypeptide sequence, determined. Drug delivery is enhanced by administering an effective amount of occludin inhibitors. These include peptides or antibodies that interact with occludin or occludin receptors. Also included are occludin antagonists, occludin receptor components, and mixtures thereof. In some embodiments, analogues of occludin surface loops that inhibit adhesion and/or barrier properties are employed. Administration can be local or systemic; local administration in a pharmaceutically acceptable carrier is preferred in some embodiments.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

WO 97/33605

PCT/US97/05809

**HUMAN OCCLUDIN, ITS USES AND ENHANCEMENT OF DRUG
ABSORPTION USING OCCLUDIN INHIBITORS**

Related Application Data

This is a continuation-in-part of co-pending U.S. patent application serial number 60,013,625, filed March 15, 1996.

Technical Field

- 5 This invention relates primarily to the enhancement of drug absorption across epithelial and endothelial barriers using occludin inhibitors.

Background of the Invention

- 10 In mammalian cells, intercellular junctions are typically categorized into four types, based on early electron microscope studies: adherens junctions, desmosomes, gap junctions, and tight junctions. Recent research interest has focused on the molecular organization and functions of these junctions, to not only explain cell-cell interactions and communication within multi-cellular organisms, but also to regulate paracellular permeability for therapeutic purposes.

- 15 Drug absorption across epithelial and endothelial tissue is limited in several stages. One important barrier is created by intercellular tight junctions

WO 97/33605

PCT/US97/05809

- 2 -

which limit movement of substances between cells (Anderson, J.M., and Van Itallie, C.M., *Am. J. Physiol. (GI and Liver)* 269:G467-G475 (1995)). The tight junction barrier appears to be created by extracellular contacts of a transmembrane protein called occludin. The protein was originally cloned from the chicken

5 (Furuse, M., *et al.*, *J. Cell Biol.* 123: 1777-1788 (1993)). Occludin has subsequently been cloned and sequenced from human, mouse, dog and rat kangaroo (Ando-Akatsuka, Y., *et al.*, *J Cell Biology* 133: 43-47 (1996). Human occludin has also been cloned and sequenced by applicants (Genbank Accession U53823; see SEQ ID NOs 1 and 2 and Figure 1).

10 Tight junctions create a regulated paracellular barrier to the movement of water, solutes, macromolecules, immune cells, and the like between and among both epithelial and endothelial cells. New evidence has elucidated information about proteins involved in this dynamic regulation.

It would be beneficial to utilize this information to alter paracellular

15 permeability for specific medical purposes.

Summary of the Invention

It is an object of the invention to provide the sequence of cloned human

20 occludin.

It is another object of the invention to provide a method for the selective enhancement of transmucosal or transvascular drug delivery. It has been demonstrated that peptides corresponding to the extracellular fragments of human occludin are capable of inhibiting cell to cell adhesion (see the examples that follow). Further it has been shown that peptides corresponding to extracellular

25 sequences of occludin can interrupt the transmonolayer barrier properties of

WO 97/33605

PCT/US97/05809

- 3 -

cultured epithelial cells (Wong and Gumbiner, B. (1997) *J. Cell Biology* 136:399-409. Also see Figure 2.

These and other objects are accomplished by the present invention, which provides cloned human occludin and methods for altering occludin's barrier properties. The sequence of occludin provides occludin-based screening assays for occludin inhibitors such as binding assays, assays that measure adhesive properties, and the like, particularly those involving the extracellular loop sequences given below. In some embodiments, fibroblast adhesion measurements, *e.g.*, those employing electrical resistance or transmonolayer flux measurements are employed.

In other embodiments, the invention provides a method for enhancing drug delivery by disrupting the intercellular seal provided by occludin. In accordance with this embodiment of the invention, effective amounts of occludin inhibitors and/or mimics such as peptide fragments of occludin and the like compounds identified in screens are administered to a patient, typically in combination with another drug or a mixture of drugs. Mimics include, but are not limited to, peptides analogous to sequences disclosed herein that have sequence alterations that enhance solubility or other properties desirable for achieving desirable pharmacological effects described hereafter. Administration can be local or systemic; local administration is preferred in some embodiments.

Brief Description of the Figures

Figure 1 sets out the cDNA sequence of human occludin (SEQ ID NO 1) and the deduced amino acid sequence (SEQ ID NO 2). The figure employs standard one-letter nomenclature for the amino acids: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr. The extracellular

WO 97/33605

PCT/US97/05809

- 4 -

loops described hereafter are denoted as boxed regions, as are the positions wherein translation starts and stops.

Figure 2 is a graph showing inhibition of occludin-dependent intercellular adhesion using extracellular loop peptides corresponding to the N-terminal half of occludin extracellular loop #1 (peptide 1, SEQ ID NO 3) and the C-terminal half of extracellular loop #1 (peptide 2, SEQ ID NO 4) compared with an irrelevant peptide (peptide 3, SEQ ID NO 6). Caco-2 cells were plated on Falcon transwell cell culture inserts in DMEM supplemented with 10% fetal bovine serum and allowed to attach for 24 hours. Confluent monolayers were washed three times with calcium- and magnesium-free phosphate buffered saline and incubated in low calcium medium (supplemented with 5% dialyzed fetal bovine serum) for 24 hours. Transepithelial electrical resistance was measured (time 0) and an equal volume of 2X DMEM/20% fetal bovine serum was added to all wells. To some wells, peptides were added with the fresh media. All peptides were added to a final concentration of 100 μ M; transepithelial electrical resistance was measured in 3 wells of each treatment condition. Symbols represent the mean and standard deviation of each measurement.

Figure 3 show graphs comparing aggregation of human occludin-transfected cell lines. Occludin is expressed from a butyrate-inducible promoter. Aggregation kinetics of the various fibroblast cells lines (control, untransfected NRK, rat-1 and L-cells) and occludin-transfected cell lines (N2occ, R9occ, L5occ) without (-) and with (+) 16 hours of butyrate induction as measured with the Coulter counter. The decrease in the relative percent of particles ($N_t/N_0 \times 100$) as a function of time indicates the extent of aggregation. The results from at least three separate experiments are combined; (*P<0.01, ANOVA).

Figure 4 compares aggregation in rat-1 cell clones. The difference in the percent of adhesion ($N_t/N_0 \times 100$) at 80 min in rat-1 cells without (-) and with (+) butyrate treatment is compared for the parent cell line (rat-1) and two occludin-

WO 97/33605

PCT/US97/05809

- 5 -

transfected clones (R9occ and R11occ) which express different levels of human occludin. Results from three separate experiments are combined.

Figure 5 shows aggregation of N2occ cells in the absence or presence of various concentrations of synthetic peptides. Peptides were added in equal volumes of PBS at the start of the incubation period; extent of aggregation is shown after 80 minutes of incubation. Loop peptides represent contiguous sequences in the first extracellular loop (SEQ ID NOs 3 and 4); the internal peptide has the same pI as loop peptide #1. Peptide sequences are given in the Examples section. One of three experiments with identical results is shown.

10 Detailed Description of the Invention

This invention is based upon the elucidation of the sequence of human occludin. DNA sequences encoding human occludin were cloned, characterized, and sequenced, and the amino acid sequence of the polypeptide was deduced. See Figure 1. The data show that the two extracellular domains of human occludin contain a highly unique amino acid sequence rich in tyrosine and glycine residues. The more amino-terminal extracellular domain of human occludin contains nine repeats of the dipeptide glycine/tyrosine. Comparison of the 5 available deduced amino acid sequences of occludin from different species demonstrates that the first loop in all species is very tyrosine- and glycine-rich. However, the amino acid sequence itself is not well conserved suggesting something unique about the chemical properties but not necessarily the specific amino acid sequence. In contrast, comparison of the second extracellular loop demonstrates a very conserved sequence. Both extracellular loops then provide a unique opportunity to develop inhibitors. In the case of loop 1, this would be more dependent on its unusual chemistry or be species-specific. Drugs developed for human use may not be active in other animal species. In the case of the second loop, there is a specific sequence requirement conserved across species.

WO 97/33605

PCT/US97/05809

- 6 -

This invention thus provides isolated and purified human occludin, and fragments thereof useful for therapeutic purposes, and purified and isolated DNA comprising DNA sequences encoding human occludin (and fragments thereof), and purified and isolated DNA comprising DNA sequences which hybridize under
5 stringent conditions with sequences encoding the protein or its fragments. Also provided are RNA sequences corresponding to the DNA sequences.

In one embodiment, the invention provides purified and isolated DNA encoding the deduced human occludin set out in Figure 1 (residues 534 to 2003 of
10 SEQ ID NO: 1), degenerate and complementary sequences, and sequences that hybridize under stringent conditions with the sequence. Also encompassed by this invention are cloned sequences defining human occludin, which can then be used to transform or transfect a host cell for protein expression using standard means. Also encompassed by this invention are DNA sequences homologous or closely
15 related to complementary DNA described herein, namely DNA sequences which hybridize to occludin cDNA, particularly under stringent conditions that result in pairing only between nucleic acid fragments that have a high frequency of complementary base sequences, and RNA corresponding thereto. In addition to the occludin-encoding sequences, DNA encompassed by this invention may contain additional sequences, depending upon vector construction sequences, that facilitate
20 expression of the gene. Also encompassed are sequences encoding synthetic occludin peptides or polypeptides exhibiting activity and structure similar to isolated or cloned occludin, particularly those that are active in inhibiting epithelial and endothelial barriers. These are referred to herein as "biological equivalents or
25 variants," and in some embodiments have at least about 80%, preferably at least about 90% sequence homology with occludin.

Because of the degeneracy of the genetic code, a variety of codon change combinations can be selected to form DNA that encodes occludin of this invention, so that any nucleotide deletion(s), addition(s), or point mutation(s) that

WO 97/33605

PCT/US97/05809

- 7 -

result in a DNA encoding the protein are encompassed by this invention. Since certain codons are more efficient for polypeptide expression in certain types of organisms, the selection of gene alterations to yield DNA material that codes for the protein of this invention are preferably those that yield the most efficient
5 expression in the type of organism which is to serve as the host of the recombinant vector. Altered codon selection may also depend upon vector construction considerations.

DNA starting material which is employed to form DNA coding for occludin peptides or polypeptides of this invention may be natural, recombinant or
10 synthetic. Thus, DNA starting material isolated from tissue or tissue culture, constructed from oligonucleotides using conventional methods, obtained commercially, or prepared by isolating RNA coding for occludin, and using this RNA to synthesize single-stranded cDNA which is used as a template to synthesize the corresponding double stranded DNA, can be employed to prepare DNA of this
15 invention.

DNA encoding the peptides or polypeptides of this invention, or RNA corresponding thereto, are then inserted into a vector, and the recombinant vector used to transform a microbial host organism. Example host organisms useful in the invention include, but are not limited to, bacterial (e.g., *E. coli* or *B. subtilis*),
20 yeast (e.g., *S. cerevisiae*), mammalian (e.g., mouse fibroblast or other cell line) or insect (e.g., baculovirus expression system) cells. This invention thus also provides novel, biologically functional viral and circular plasmid RNA and DNA vectors incorporating RNA and DNA sequences describing occludin or occludin fragments generated by standard means. Culture of host organisms stably trans-
25 formed or transfected with such vectors under conditions facilitative of large scale expression of the exogenous, vector-borne DNA or RNA sequences and isolation of the desired polypeptides from the growth medium, cellular lysates, or cellular membrane fractions yields the desired products.

WO 97/33605

PCT/US97/05809

- 8 -

The present invention thus provides for the total and/or partial manufacture of DNA sequences coding for occludin, and including such advantageous characteristics as incorporation of codons preferred for expression by selected non-mammalian hosts, provision of sites of cleavage by restriction endonuclease enzymes, and provision of additional initial, terminal or intermediate DNA sequences which facilitate construction of readily expressed vectors. Correspondingly, the present invention provides for manufacture (and development by site specific mutagenesis of cDNA and genomic DNA) of DNA sequences coding for microbial expression of occludin analogues which differ from the form specifically described herein in terms of identity or location of one or more amino acid residues (*i.e.*, deletion analogues containing less than all of the residues specified for the protein, and/or substitution analogues wherein one or more residues are added to a terminal or a medial portion of the polypeptide), and which share or alter the biological properties of occludin described herein.

DNA (and RNA) sequences of this invention code for all sequences useful in securing expression in procaryotic or eucaryotic host cells of peptide or polypeptide products having at least a part of the primary structural conformation, and one or more of the biological properties of occludin which are comprehended by: (a) the DNA sequences encoding occludin as described herein, or complementary strands; (b) DNA sequences which hybridize (under hybridization conditions) to DNA sequences defined in (a) or fragments thereof; and (c) DNA sequences which, but for the degeneracy of the genetic code, would hybridize to the DNA sequences defined in (a) and (b) above. Specifically comprehended are genomic DNA sequences encoding allelic variant forms of occludin included therein, and sequences encoding RNA, fragments thereof, and analogues wherein RNA or DNA sequences may incorporate codons facilitating transcription or RNA replication of messenger RNA in non-vertebrate hosts.

The results in the examples that follow show that the human cDNA can be transfected into cultured fibroblasts. Fibroblasts do not express occludin; they

WO 97/33605

PCT/US97/05809

- 9 -

live as single cells and do not form barriers. Introduction of occludin into fibroblasts causes them to adhere to one another. Two separate peptides corresponding to the first and second half of the first extracellular loop have been shown to inhibit the cell/cell adhesion in occludin-transfected fibroblasts in a quantitative assay that measures cell-to-cell adhesion. This shows that the first loop is involved in an adhesive event and that the peptides themselves are competitive inhibitors of adhesion. Figure 2 provides data showing this same peptide inhibits transmonolayer electrical resistance in cultured human colonic epithelial cells. Thus, the peptides are occludin inhibitors. Data reported in Wong and Gumbiner (cited above) demonstrate that the second loop is able to interfere with barrier properties of cultured monolayers and increase flux of tracer molecules.

The invention thus also provides the occludin peptides or polypeptides encoded by the above-described DNA and/or RNA, obtained by isolation or recombinant means. In one embodiment, for example, the invention provides a polypeptide having an amino acid sequence depicted in residues numbered 58 to 104 of human occludin depicted in Figure 1 (residues 90 to 138 of SEQ ID NO 2), or fragments or biological variants thereof. In another embodiment, the invention provides a polypeptide having the amino acid sequence depicted in residues numbered 164 to 211 of the human occludin depicted in Figure 1 (residues 196 to 246 of SEQ ID NO 2), or fragments or biological variants thereof.

The invention correspondingly provides peptide mimics such as peptide fragments of occludin and functionally equivalent counterparts that demonstrate activity in barrier disruption. For example, alterations in known sequences can be performed to enhance solubility or other properties desirable for the pharmacologic effect. Since the extracellular loops are involved as receptors in adhesion and sealing, the sequences can be used in *in vivo* assays to screen for receptor ligand agents which interrupt their adhesive properties.

WO 97/33605

PCT/US97/05809

- 10 -

For the construction of shorter peptides, preferred syntheses of occludin fragments of the invention may be by standard chemical means involving the ordered assembly of the peptides from constituent amino acids. It is an advantage of the invention that since the two extracellular domains of human occludin exhibit a highly unique amino acid chemistry, rich in glycine and tyrosine, many peptides of the invention may be easily manufactured using the two constituent amino acids. Moreover, the uniqueness of the region provides a novel target for compounds which selectively disrupt occludin's seal and enhance intercellular drug delivery.

Isolation and purification of peptides and polypeptides provided by the invention are by conventional means including, for example, preparative chromatographic separations such as affinity, ion-exchange, exclusion, partition, liquid and/or gas-liquid chromatography; zone, paper, thin layer, cellulose acetate membrane, agar gel, starch gel, and/or acrylamide gel electrophoresis; immunological separations, including those using monoclonal and/or polyclonal antibody preparations; and combinations of these with each other and with other separation techniques such as centrifugation and dialysis, and the like.

It is an advantage of the invention that the isolation and purification of human occludin provides a polypeptide that is useful in the development of compounds that selectively alter the intercellular seal for the purpose of enhancing transmucosal and transendothelial drug delivery. The delivery of larger materials, e.g., viral particles used for therapeutic gene delivery, can also be enhanced.

Peptide regions which interact with the sealing surface and disrupt the barrier properties define protein regions responsible for sealing. Synthetic compounds mimicking this chemistry can then be tested for similar properties. In this approach, occludin is considered a cell surface receptor whose adhesion creates the barrier. If the seal is formed by homotypic contacts, then occludin is both the receptor and its ligand. The extracellular domains, or representative peptides, are

WO 97/33605

FCT/US97/05809

- 11 -

used to establish *in vitro* binding assays, and these assays are used to screen for compounds that disrupt binding. Recombinant fragments could be used, for example, in routine ELISA binding assays, phage display libraries, bacterial libraries or other known methods that screen large combinations of peptide sequences or other compounds.

This invention thus provides a method for screening for occludin inhibitors. As used herein, an occludin inhibitor is any substance that enhances paracellular permeability through specific interaction with extracellular protein sequences of occludin. Occludin inhibitors are identified in screening assays when test compounds inhibit a functional property of occludin. *In vitro* assays, for example, test compounds that bind to the extracellular loops of occludin expressed as recombinant or synthetic peptides, fragments or derivatives thereof, particularly assays that bind to residues 90 to 138 of SEQ ID NO 2 and/or residues 196 to 246 of SEQ ID NO 2 (or fragments or variants, and mixtures of these). Any standard binding assay can be used to screen the interaction of large collections of test compounds with a target. Compounds that bind to occludin are potential occludin inhibitors.

Alternatively, *in vitro* assays based on the interruption of adhesive properties of the extracellular protein sequences of occludin expressed as recombinant, synthetic or altered sequences, or fragments thereof, for binding other sequences of occludin or occludin receptors are employed. For example, a fluorescent labelled fragment of occludin is released into the fluid phase and detected spectrophotometrically. Other assays include fibroblast adhesion assays such as those described in the examples that follow, or binding of occludin-transfected fibroblasts to a solid phase on which test compounds are bound. Some assays involve transmonolayer flux measurements. Any test compound which inhibits occludin binding is identified as an occludin inhibitor for further evaluation.

WO 97/33605

PCT/US97/05809

- 12 -

In one embodiment of the invention, the method screens for the presence or absence of occludin inhibition by a test sample by (a) adding the test sample to an *in vitro* culture of epithelial or endothelial cells; (b) adding an occludin loop peptide and the test sample to a second culture of the same cells; (c) incubating the cultures for such time under such conditions sufficient to observe growth in cultures containing no test sample; (d) comparing the extent of adhesion in cultures with test sample and peptide with the extent of adhesion in cultures with no peptide; and (e) determining the presence of inhibition by observation of more adhesion in cultures with test sample and less adhesion in cultures having test sample and peptide. In an alternate embodiment, the method for screening for the presence or absence of occludin inhibition by a test sample comprises: (a) adding the test sample to an *in vitro* culture of epithelial or endothelial cells; (b) adding an occludin loop peptide and the test sample to a second culture of the same cells; (c) adding a tracer compound to both cultures; (d) incubating the cultures for such time under such conditions sufficient to observe growth in cultures containing no test sample; (e) comparing the extent of tracer uptake in cultures with test sample and peptide with the extent of tracer uptake in cultures with no peptide; and (f) determining the presence of inhibition by observation of increased tracer uptake in cultures with test sample and decreased tracer uptake in cultures having test sample and peptide.

Compounds exhibiting activity are then tested for their ability to inhibit the barrier in cultured monolayers of epithelial cells. Compounds exhibiting activity *in vitro* in such assays are then tested *in vivo* and modified to eliminate toxic effects and optimize solubility or other properties required for certain applications. The invention provides a way to define compounds which can be co-administered with therapeutic drugs to enhance absorption to test on animals and humans. The unique sequence information is thus useful for the development therapeutically relevant compounds.

WO 97/33605

PCT/US97/05809

- 13 -

For example, in *in vitro* sealing experiments, peptides representing fragments of the sequence are first generation inhibitors. Testing those that inhibit may be further modified to provide second generation inhibitors, or be used to design mimicking compounds. Information from first generation inhibitors can also assist in screening libraries of compounds. Methods of the invention are applicable to any type of human tissue, including, but not limited to, oral and nasal mucosa, gut, dermal, blood vessel, and airway tissue.

In the practice of this aspect of the invention, drug delivery is enhanced in human patients by administration of an effective amount of an occludin inhibitor to the patient. By "occludin inhibitor" is meant any inhibitor of occludin function, occludin peptide fragments and analogues that bind to occludin receptors, antibodies to occludin or occludin fragments, occludin receptor antagonists, soluble receptor components that bind to occludin, antibodies to components of occludin receptors, and the like. Mixtures of inhibitors can also be employed, as well as inhibitors of occludin synthesis or stability. In some embodiments of the invention, inhibitors are administered with at least one other compound that enhances the inhibitory effect and/or stabilizes the inhibitor in the formulation administered.

Administration of occludin inhibitors can be local or systemic. Local administration is preferred in some embodiments. In these embodiments, at least one occludin inhibitor, preferably in association with a pharmaceutically acceptable carrier in which the inhibitor is dispersed or solubilized, is topically applied in effective amounts to the skin as a solution, lotion, cream, soap, and the like, or nasal mucosal and/or lung tissue using aerosols, inhalants, nasal drops, nasal sprays, and the like.

Systemic administration of occludin inhibitors in other embodiments can be via any method known in the art such as, for example, oral administration of lozenges, tablets, capsules, granules, or other edible compositions; intravenous, intramuscular, or intradermal administration, e.g., by sterile injections; parenteral

WO 97/33605

PCT/US97/05809

- 14 -

administration of fluids and the like. Combinations of therapies may also be employed.

The amount of occludin inhibitor necessary to bring about the therapeutic treatment is not fixed *per se*, and necessarily is dependent upon the drug delivery to be enhanced, the particular inhibitor employed, the particular drug employed in combination with occludin inhibitor, adjunct compounds in the composition administered that enhance the inhibitory effect when present, the age, weight, and clinical condition of the patient to be treated, and the concentrations of these ingredients in the formulation put together in association with a pharmaceutically acceptable carrier. Generally the dose should be sufficient to enhance drug delivery without producing unacceptable toxicity to the patient.

As mentioned above, compositions of the invention are typically applied in admixture with a pharmaceutically acceptable carrier or vehicle. Administration is facilitated and, in some cases, additional therapeutic effects are provided by the carrier. When a carrier is employed, it is necessary that the carrier be inert in the sense of not bringing about a deactivation of inhibitor, and in the sense of not bringing about any adverse effect to the patient to whom it is administered.

Suitable carriers include any that will dissolve or disperse the active ingredients at concentrations of active ingredients most suitable for use in the therapeutic treatment. Generally, even low concentrations of active ingredients in a carrier will be suitable, particularly where more frequent drug administration is required for enhancing drug therapy. It is desirable that compositions of the invention be formulated to contain amounts of inhibitor sufficient to provide enhancement of at least about 10%, preferably about 25% or higher, e.g., 50%, over the drug delivery in the absence of occludin inhibitor, or allow absorption of drugs that would otherwise not be absorbed. Accordingly, carriers will be chosen which can solubilize or disperse the active ingredients at such concentrations. Examples of such carriers include both aqueous and nonaqueous carriers. In addi-

WO 97/33605

PCT/US97/05809

- 15 -

tion, pharmaceutical compositions or formulations may also include other carriers, adjuvants, stabilizers, preservatives, dispersing agents, and the like.

It should be understood that in addition to the ingredients particularly mentioned above, formulations of the invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for nasal administration may include odors, for oral administration, flavoring agents, and for topical applications, emollients.

Alternatively, isolated and purified human occludin supplies a polypeptide that can be used to provide methods of enhancing sealing for therapeutic purposes, such as, for example, by administration of effective amounts of occludin enhancers or modifiers of the allosteric seal effectors. It is an advantage of the invention that the elucidation of the structure of human occludin provides not only a way of enhancing transmucosal and transendothelial drug delivery, but also a way of reducing permeability.

While not wishing to be bound to any theory, the efficacy of the invention appears to be related to the selectivity in targeting occludin for the alteration of the intercellular seal. No presently used method for enhancing transmucosal or transvascular drug delivery takes advantage of knowledge of the tight junction's protein composition. Most approaches propose to alter intracellular signaling mechanisms and are likely to be quite nonselective in their action. In contrast, this invention uses the highly unusual chemistry of the extracellular domains of the sealing protein itself. It is an additional advantage of the invention that the target regions of occludin are extracellular so that antagonists which remain outside of cells can be developed which avoid interfering with intracellular events. This creates the possibility for an exquisitely specific effects of anti-occludin drugs.

WO 97/33605

PCT/US97/05809

- 16 -

Examples

The following examples are presented to further illustrate and explain the present invention and should not be taken as limiting in any regard.

Example 1

5 To clone the human occludin cDNA sequence, a short sequence homologous to the chicken cDNA sequence was observed fused to an unrelated cDNA presumed to encode the product of the NAIP gene in individuals afflicted with the genetic disease Spinal Muscular Atrophy (Roy, N., *et al.*, *Cell* 80: 167-178 (1995)). It was assumed this represented a fragment of human occludin, and this
10 sequence information was used to clone the full-length human occludin cDNA using standard techniques. Human RNA was reverse transcribed and amplified with oligonucleotide primers within the region homologous to chicken occludin. The expected amplification product was cloned and used to screen a human liver cDNA library, in a phagemid vector, using standard hybridization methods.

15 Multiple overlapping cDNAs were isolated, sequenced, and encoded the full-length occludin cDNA presented in Figure 1. The deduced amino acid sequence show about 49% identity and about 66% similarity to chicken occludin. The two extracellular loop domains, residues 58-104 (residues 90 to 138 of SEQ ID NO: 2, inclusive) and 164-211 (residues 196 to 246 of SEQ ID NO: 2, inclusive), respectively, in human occludin, and residues 81-124 and 184-227 (inclusive) in chicken occludin show the same highly unusual chemistry.
20

Example 2

This example shows that occludin confers adhesiveness when expressed in fibroblasts.

WO 97/33605

PCT/US97/05809

- 17 -

cDNAs, Antibodies, Peptides and Cell Lines Employed

The 675-nucleotide occludin sequence found in the untranslated region of the human neuronal apoptosis inhibitory gene (Roy, N., *et al.*, *Cell* 80: 167-178 (1995)) was used to design PCR primers, and reverse transcription-PCR was performed using polyA⁺ mRNA from Caco-2 cells as template. The resulting cDNA fragment was used to screen a human liver library (Clontech) and a full length cDNA was isolated and sequenced (GenBank Accession U53823). A similar protocol was recently reported by Ando-Akatsuka, *et al.*, cited above, to clone the full-length human occludin, which demonstrates an exact match at the amino acid level to our sequence. The full length sequence was subcloned into the pCB6 expression vector with and without a 15 amino acid tag at the C-terminus. This tag represents the carboxy-terminus of the vesicular stomatitis virus glycoprotein (VSV-G).

A cDNA encoding the last 150 amino acids of human occludin was subcloned into the pGEX-1N vector and the resulting glutathione-S-transferase (GST) fusion protein used to generate anti-human occludin antibodies in guinea pigs. The same GST-fusion protein was also used to generate rabbit polyclonal antibodies using an accelerated immunization program referred to as PolyQuikTM. The resultant rabbit polyclonal rabbit anti-human occludin polyclonal anti-sera was affinity purified using a GST-occludin coupled gel. Rabbit polyclonal anti-peptide antibodies raised against amino acids 90-112 of human occludin and two contiguous peptides: peptide #1 (CDRGYGTSLGGSVGYPGGSGFG, SEQ ID NO 3) and peptide #2 (CSYGSGYGYGYGYGYGGYTDPR, SEQ ID NO 4) were employed. Together these contiguous peptides compose the putative first extracellular loop of the occludin protein. Amino terminal cysteine residues are not part of the occludin sequence but were added to allow conjugation for antibody production. Because of the highly repetitive nature of the amino acid sequence of loop #1, it was difficult to design a control peptide by "scrambling" the sequence. Instead, a peptide from the putative cytoplasmic N-terminal region of occludin (NHYAPSNDIYGGEMVHRPML, SEQ ID NO 5), with the same isoelectric point (pI=6.2) as peptide #1, was used. Anti-ZO-1 antibody, secondary antibodies

WO 97/33605

PCT/US97/05809

- 18 -

(FITC and Texas Red labelled) for immunofluorescence are affinity-purified, species-specific from Jackson Immunoresearch Laboratories (Westover, IA) and for immunoblots from Amersham Corp. (Arlington Heights, IL) and Chemicon International, Inc. (Temecula, CA). Anti-VSV-G antibody was from MBL (Nagoya, Japan).

Tissue Culture and Cell Transfection

All cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Atlanta Biologicals, Norcross, GA) and antibiotics in 5% CO₂. Cells were transfected by calcium phosphate coprecipitation (Chen, C.A., and Okayama, A., *Biotechniques* 6: 632-638 (1988)); transient transfectants were induced with 5 mM sodium butyrate for 16-20 hours before immunofluorescent analysis. Occludin localization experiments were originally attempted after transient transfections, but results were variable and only results from stable cell lines are reported in this example. Stable cell lines were selected with 600 µg/ml G418 (Gibco BRL) for 10 days, at which time resistant clones were analyzed for occludin expression by immunofluorescence. Occludin-positive cells were maintained in 250 µg/ml G418.

Immunoblotting and Immunofluorescence

For immunoblot analysis, confluent Caco-2 cells were rinsed in phosphate-buffered saline (PBS) and lysed in sodium dodecyl sulfate (SDS) sample buffer and heated to 95°C for 10 minutes. Control and stable occludin-expressing cell lines were plated at subconfluent density, allowed to attach and spread for 8 hours, and induced with 5 mM sodium butyrate for 16-20 hours. Cells were rinsed with PBS and samples prepared as above. Protein samples were separated by SDS 10% PAGE (Laemmli, U.K., *Nature* 227: 680-685 (1970)) and transferred to nitrocellulose (Towbin, H., *et al.*, *Proc. Nat. Acad. Sci. USA* 76: 4350-4354 (1979)). Nonspecific protein binding was blocked with 10% nonfat dry milk, 0.1% Tween-20 in PBS for at least 1 hour at room temperature. Anti-occludin antibody (rabbit anti-human) was used at 1:1000 dilution, others as

WO 97/33605

PCT/US97/05809

- 19 -

indicated in figure legends. Detection was by enhanced chemiluminescence (ECL, Amersham).

For immunofluorescent localization studies, cells were grown on glass coverslips. To demonstrate that the human occludin construct could be expressed and targeted appropriately in tight junction-containing cells, MDCK cells were used for the initial transient transfection assays. MDCK cells were transfected and induced with sodium butyrate as described above and stable cell lines were plated and induced as described for immunoblots. Cells were washed with PBS, fixed in 1% paraformaldehyde in PBS, extracted with 0.1% Triton-X 100 and quenched with 50 mM NH_4Cl in PBS. In experiments to test the accessibility to the anti-peptide #1 antibody, incubation of the primary antibody was performed without permeabilization of cells with Triton-X 100. Cells were blocked for 1 hour in PBS plus 2% goat serum, incubated in primary antibodies (anti-VSV-G at 10 ug/ml, guinea pig anti-occludin at 1:250, and anti-ZO-1 at 1:300; affinity-purified anti-peptide #1 antibody at 1:10) for 1 hour, washed and incubated in affinity-purified secondary antibodies (1:100) for 1 hour. Cells were washed, dipped in H_2O and mounted in Vectashield (Vector Laboratories). The samples were examined with a Nikon Microphot-FX epifluorescence microscope; photographs were taken with TMAX400 film (Kodak, Rochester, NY) using the automatic exposure setting.

Cell Adhesion Assay

Adhesion of stably transfected cell lines was measured by a modification of the procedure described by Wesseling, J., *et al.*, *Mol. Biol. Cell* 7:565-577 (1996). Cell lines were plated and induced with sodium butyrate as described above. Cell layers were rinsed twice with Ca^{2+} - Mg^{2+} -free PBS and then incubated for 30 minutes in Ca^{2+} - Mg^{2+} -free PBS plus 1 mM EDTA and 0.1 mg/ml DNase. After 30 minutes, cells were mechanically dissociated, counted and resuspended at a concentration of 2.5×10^5 cells/ml in Ca^{2+} - Mg^{2+} -free PBS, 1 mM EDTA and 0.1 mg/ml DNase. For each condition, the adhesion assay was performed in duplicate in two 50-ml conical tubes on a rotating platform at 80 rpm at 25°C. At

WO 97/33605

PCT/US97/05809

- 20 -

each time point, the number of particles in two 175 ul aliquot of each tube was determined in a Coulter Counter (Hialeah, FL). The amount of adhesion was represented by N_t/N_0 , where N_0 was the initial number of particles in each sample (the starting number of single cells), and N_t was the number at each time point.

5 100% of cells were single at the beginning of all assays, as determined by phase-contrast microscopy. Some experiments were performed in the presence of the peptides described above.

Anti-human Occludin Antibodies

As described above, occludin cDNAs were isolated from a human liver library. The C-terminal 150 amino acids were subcloned into a pGEX vector and the resulting GST-fusion protein was used to generate polyclonal antibodies in guinea pigs. Use of these antibodies in Western blot analysis of the human colonic cell line, Caco-2, identified an antigen (doublet) at about 65 kDa, the same size as the antigen recognized previously (Fallon, M.B., et al., *Am. J. Physiol.*

10 260: C1057-1062 (1995)) by anti-chicken occludin antibody. Other antibodies used in these studies include a commercially available affinity-purified anti-human occludin rabbit polyclonal raised against the same C-terminal fusion protein and an anti-peptide antibody raised against a 23 amino acid sequence from the putative first extracellular loop (CDRGYGTSLGGSVGYPGGSGFG, SEQ ID NO 3).

20 All antibodies recognize a doublet in Caco-2 cells. Multiple bands have been reported before and may result from an uncharacterized posttranslational modification. In addition, anti-chicken occludin antibodies recognize a smaller molecular weight protein of about 20 kDa; the nature of this cross-reacting epitope is unknown. Thus, all antibodies used in the present studies exclusively recognize
25 occludin; results with the anti-chicken antibodies are shown to compare with our previously characterized antibodies but were not used for experiments reported herein.

WO 97/33605

PCT/US97/05809

- 21 -

Expression of Transfected Human Occludin in MDCK Cells

To confirm that transfected human occludin could localize appropriately in cells which normally expressed occludin, MDCK cells were transiently transfected with VSV-G-tagged human occludin cloned in the pCB6 vector. Expression was induced with sodium butyrate and cells stained for ZO-1 and for VSV-G. ZO-1 immunofluorescence reveals the typical reticular pattern of tight junction staining. Immunofluorescence using the VSV-G antibody shows that in cells that expressed low levels of human occludin, the transfected protein was concentrated at sites of cell-cell contact, although higher expressing cells also expressed considerable occludin elsewhere in the cell. It was concluded that the VSV-G-tagged human occludin can target appropriately to tight junctions in cultured epithelial cells which have pre-existing tight junctions.

Expression of Transfected Human Occludin in Fibroblast Cell Lines

The expression and localization of occludin were examined in three fibroblast cell lines that do not form recognizable tight junctions or electrically resistive monolayers in culture. NRK cells, Rat-1 cells and L-cells do not normally express detectable occludin by Western blot analysis. This apparent lack of expression is not due to an inability of the anti-human occludin antibody to recognize rodent occludin, since a slightly smaller form of occludin is easily detected in immunoblots from whole rat kidney. Fibroblast cell lines were transfected with the pCB6 occludin vector and stable cell lines were selected on the basis of antibiotic resistance with G418. G418-resistant clonal cell lines were screened by immunofluorescence and of the small number of occludin-expressing cell lines, none had more than about 40% of the cells expressing detectable occludin. Occludin was readily detectable by Western blot analysis in some stable cell lines, and was inducible in all cell lines after 18 hours exposure to 5 mM sodium butyrate. The transfected human occludin exhibited a higher apparent molecular weight characteristic of human occludin when compared with rat occludin. The three fibroblast cell clones used for most of the following experiments could be induced to express approximately equal amounts of the occludin

WO 97/33605

PCT/US97/05889

- 22 -

transgene. The inducible nature of occludin expression allowed comparison of uninduced with induced cell lines, as well as comparison to non-transfected cells. In addition, a Rat-1 cell clone (R110cc) expressing about one-third less occludin was used in some studies to look at the effect of expressing a lower level of occludin.

Yonemura, S., *et al.*, *J. Cell Sci.* 108:127-142 (1995) previously described that in NRK cells, ZO-1 localizes to sites of cell-cell contact, along with other proteins normally associated with adherens junctions. This ZO-1 distribution was also noted in NRK cells, as well as in another fibroblast line, Rat-1 cells, although the latter cells are not as flat and tend to have less regularly spaced cell contacts. In both NRK cells and in rat-1 cells, human occludin colocalized with ZO-1 at sites of cell-cell contact, as well as showing a diffuse and lower level of expression over the entire plasma membrane. Occludin did not appear to be more concentrated between two neighboring cells when both expressed occludin, suggesting that in these transfected cells, intercellular occludin-occludin interactions do not appear to appreciably stabilize occludin localization. In fact, occludin appears to concentrate with ZO-1 even when the adjacent cell does not contain detectable occludin. Both transfected cell lines also had small amounts of occludin expressed elsewhere in the cell, possibly in intracellular vesicles and plasma membrane aggregates. In contrast, mouse L-cells, which lack E-cadherin and adherens-like junctions (Angres, B., *et al.*, *J. Cell Biol.* 134(2):1-10 (1996)) concentrated neither ZO-1, nor occludin at sites of cell-cell contact. Both appear diffusely distributed over the plasma membrane, although ZO-1 but not occludin, is concentrated in puncta on the apical surface.

25 *Occludin Expression Confers Adhesion on NRK and Rat-1 cells, but not L-cells*

The ability of transfected occludin to confer adhesion onto fibroblast cell lines was assessed using a suspended cell aggregation assay (Weiseling, J., *et al.*, *Mol. Biol. Cell* 7: 565-577 (1996)). All cells were counted as single particles at the beginning of the assay and any decrease in the fraction of particles over the 80 minute assay was the result of aggregates which are excluded by the Coulter

WO 97/33605

ICT/US97/05809

- 23 -

Counter. Aggregation was qualitatively confirmed by light microscopic inspection and correlated with results quantified by the Coulter Counter. Immunofluorescence confirmed that ZO-1 and occludin are clustered between adherent cells after the 80 minute assay.

- 5 As shown in Figure 3, human occludin promoted cell aggregation in the absence of calcium in both Rat-1 cells and in NRK fibroblasts, but not in L-cells. Expression of occludin in NRK and Rat-1 fibroblasts induced a steeper slope ($[N_t/N_0]/\text{time}$) and lower final number of particles per unit volume at 80 minutes, the longest time assayed. In addition, when two Rat-1 clones with differing levels
- 10 of occludin expression were tested in this assay, the degree of adhesion at 80 minutes correlated in a positive way with the level of occludin expression (Figure 4). It was not determined whether the degree of adhesion measured in this assay correlates with the level of occludin expressed per cell or the percentage of cells
- 15 expressing occludin. The effect of adhesion was not due to treatment of cells with butyrate, since adding butyrate to fibroblasts transfected with pCB6 without the occludin cDNA did not result in increased adhesion. The value of $[N_t/N_0 \times 100]$ never dropped below 40% suggesting some cells were nonadhesive. Although immunofluorescence studies showed not all cells express occludin, attempts to
- 20 separate aggregated from single cells and determine whether nonaggregating cells were those showing less or no occludin expression were unsuccessful.

Antibody Accessibility Reveals Exposure of Occludin on the Extracellular Surface

- The model for occludin topography predicts a region rich in glycine and tyrosine is positioned as the first, or more N-terminal, of the two extracellular loops. To determine whether these sequences are exposed on the outside of the
- 25 cell, their availability in nonpermeabilized living cells to an antibody raised against a synthetic peptide corresponding to the first 23 residues of this loop were assessed. As determined by Western blotting, these antibodies have very low affinity and consistent results were only obtained using human Caco-2 cells which contain many fold higher levels of occludin than the transfected cells. The C-
- 30 terminal ZO-1 binding domain of occludin was previously shown to be intracellu-

WO 97/33605

PCT/US97/05809

- 24 -

lar (Furuse, *et al.*, cited above) and consistent with this, immunofluorescence analysis of nonpermeabilized Caco-2 cells stained with an antibody to this region reveals no specific staining. After detergent permeabilization, the same antibody reveals a typical reticular occludin staining pattern. Nonpermeabilized Caco-2
5 cells incubated in 1 mM EDTA and antibody raised against the putative extracellular sequence shows a similar pattern of staining, suggesting this sequence is in fact exposed on cell surface. Less labeling was observed when cells were not exposed to EDTA, suggesting the sequences are not available to bind antibodies unless contacts are first disrupted by chelating divalent cations. However, even after
10 exposure to EDTA the antigen is not uniformly accessible. However, the antibody accessibility proves the putative extracellular loop is indeed extracellular, and a target for occludin inhibitors.

Occludin Peptides Inhibit Occludin-induced Adhesion

To determine if the extracellular sequences of occludin are directly
15 involved in the adhesion observed in the occludin-transfected fibroblasts, an assessment of competition for the adhesive function using synthetic peptides corresponding to both halves of the first putative extracellular loop was attempted (Figure 5). Peptides were tested at 1, 10 and 100 μ M. Both peptides #1 and #2 completely inhibited adhesion in both the Rat-1 and NRK cell clones at 100 μ M
20 (Rat-1 cell). Peptide #1 reversed approximately half the adhesion at 10 μ M, suggesting an apparent K_i in this range. The apparent K_i for peptide #2 was reproducibly somewhat higher, in the range between 10-100 μ M. These apparent inhibition constants suggest this region of occludin participates in a relatively low affinity binding interaction. An internal occludin peptide added over the same
25 concentration range was ineffective at inhibiting occludin-dependent cell adhesion.

Discussion and Conclusions

Thus, transfected human occludin colocalizes with ZO-1 at sites of cell-cell contact in some fibroblast cell lines, and cells in which occludin colocalizes
30 acquire adhesiveness. In addition, it was shown shown that the putative first

WO 97/33605

PCT/US97/05809

- 25 -

extracellular loop of occludin is accessible to antibodies in the absence of cell permeabilization, thus supporting the predicted transmembrane topology originally based on hydrophobicity profiles (Furuse, *et al.*, cited above). Finally, it was demonstrated that peptides with sequences matching this extracellular loop decrease cell adhesion in occludin-expressing fibroblasts in a dose-dependent fashion. These data imply that this loop participates in an adhesive interaction, and the peptides are acting as competitive inhibitors at the adhesive surface.

The human occludin used herein was capable of properly targeting when expressed in cultured epithelial cells which contain preformed tight junctions (MDCK cells). In contrast, when expressed ectopically in fibroblasts, occludin localized only at cell-cell contacts in lines already capable of localizing ZO-1, i.e. NRK cells and Rat-1 cells. ZO-1 is known to bind directly to occludin through a 150 amino domain at the C-terminus of occludin (Furuse, *et al.*, cited above). Without wishing to be bound to any theory, it appears from observations in fibroblasts is that occludin uses prelocalized ZO-1 as its predominate targeting signal. This observation is different than that of Balda, M.S., *et al.*, *J. Cell Biol.* 134(4): 1031-1049 (1996), who expressed a truncated form of occludin without the ZO-1 binding domain in MDCK cells and found it still capable of targeting to the tight junction. Because these cells already contain preformed tight junctions, lateral interactions between occludin proteins within the same cell or between cells could account for localization. However, in the absence of endogenous occludin, de novo targeting of occludin in fibroblasts appears to require binding to ZO-1, not lateral or cell-cell association between occludin proteins.

Neither ZO-1 nor ectopically-expressed occludin was capable of localizing to cell contacts in the L-cell clone used for this study. Occludin was diffusely distributed over the cell, again suggesting that accumulation at cell contacts is not a strong intrinsic property of occludin. This L-cell clone was previously shown to express very low levels of cadherin, and consistent with this it lacks Ca^{2+} -dependent adhesion (Angres *et al.*, 1996). It was recently shown that the cadherin-binding protein β -catenin binds to ZO-1 early after initiation of cell contacts, and that these proteins subsequently sort over time into distinct tight and

WO 97/33605

PCT/US97/05809

- 26 -

adherens junctions (Rajasekaran, A.K., *et al.*, *J. Cell Biol.* 132:451-463 (1996)).

Interaction with cadherin through β -catenin provides a tentative explanation for why ZO-1 clusters at cadherin contacts in occludin-null cells and why ectopically-expressed occludin fails to cluster in cells which lack cadherin. The cell-cell

- 5 contacts of NRK cells have been shown to contain several components of adherens-type junctions, vinculin, α -actinin (Yonemura, S., *et al.*, *J. Cell Sci.* 108:127-142 (1995)), thus direct or indirect interaction with any of these could conceivably also provide a mechanism to recruit ZO-1 and occludin.

- The results suggest a correlation in fibroblasts between the ability of
10 occludin to cluster at cell-cell contacts and confer adhesiveness. Without wishing to be bound to any theory, one possible explanation is that occludin molecules must cluster to gain sufficient cooperativity for adhesiveness to be detected in the assay employed here. Other circumstantial evidence also suggests occludin's adhesiveness is not inherently high. For example, as judged by immunofluores-
15 cence, no more occludin accumulates between two fibroblasts which both express occludin than between null cells and expressing cells. In addition, even when expressed on two adjacent cells, occludin never promotes a continuous linear, tight junction-like contact and its expression does not seem to morphologically alter the pre-existent ZO-1 containing contact. Another explanation for the correlation
20 between clustering and adhesion might be that occludin must interact with cytoplasmic proteins present in the plaque to induce an adhesive conformation. Both models are consistent with the known properties of other adhesion molecules, such as the integrins, which increase adhesion through clustering as well as through conformational changes induced from the cytoplasmic side (Dehar, S., and
25 Hannigan, G.E., *Current Opinion in Cell Biology* 8: 657-669 (1996)).

- McCarthy, K.M., *et al.*, *J. Cell Sci.* 109:2287-2298 (1996) demonstrated the colocalization of ZO-1 and chicken occludin in MDCK cells cultured in low calcium, both in vesicular structures within cells and occasionally between cell pairs, consistent with the idea that ZO-1-occludin interactions can be maintained in
30 the absence of Ca^{2+} . It was demonstrated herein that occludin is adhesive in the absence of calcium, although one possibility is that occludin merely enhances

WO 97/33685

PCT/US97/05809

- 27 -

cadherin-based adhesion, or adhesion due to other cell surface proteins, even in low calcium. It seems more likely that the longstanding observation that tight junction formation is dependent on calcium-dependent cadherin-dependent cell contact may be based on the requirement of cadherin to induce the highly organized and adhesive state of occludin within the tight junction and not a requirement for cadherin as a co-adhesive receptor. Contrasting results in NRK and Rat-1 cells with L-cells suggests the testable hypothesis that clustering and or interaction with ZO-1, and not cadherin per se is required to observe adhesion.

Occludin has been proposed to have two extracellular loops, based on four predicted hydrophobic transmembrane helices and immunologic evidence that the C-terminus is intracellular (Furuse, *et al.*, cited above). It was confirmed that at least the first of these loops is in fact extracellular, since it is accessible in a nonpermeabilized cell to an antibody generated to a peptide sequence contained within this loop. This example focuses on the first extracellular loop because it is the least conserved and thus may provide species-specific recognition. Recent work of Wong and Gumbiner, cited above, have demonstrated that a peptide consisting of the chicken sequence for the second loop blocked transepithelial electrical resistance when applied to cultured monolayers of *Xenopus* A6 cells. In their assay, a peptide consisting of the first loop of the chicken sequence had no effect on transepithelial electrical resistance, consistent with the possibility for a species specific sequence requirement.

It was shown that two separate peptides containing contiguous sequences of the first extracellular loop are both capable of inhibiting adhesion in the occludin-transfected fibroblasts. Similar methods have been used to inhibit the function of other cell adhesion molecules; for example, small peptides containing extracellular loop sequences for connexins delay gap junction formation (Warner, A., *et al.*, *J. Physiol.* 488(3):721-728 (1995)), and a cadherin extracellular peptide inhibits embryo compaction (Blaschuk, O.W., *et al.*, *Dev. Biol.* 139(1):227-229 (1990)) and contact-dependent granulosa cell apoptosis (Peluso, J.J., *et al.*, *Endocrin.* 137(4):1196-1203 (1996)). While not wishing to be bound to any theory, it seems that the extracellular loops of occludin are involved in binding a

WO 97/33605

PCT/US97/05809

- 28 -

protein on the adjacent cell, either through a homophilic interaction or with some other binding partner. Consistent with the possibility that occludin is a homophilic adhesion protein is its induction of adhesion in previously occludin-null fibroblasts.

The apparent K_d in the fibroblast assay for both peptides is in the range of 10-100 μ M, suggesting a relatively low affinity. The observation that both non-overlapping peptides, which together represent the entire first loop, separately inhibit adhesion suggests the protein interaction surface may include the entire loop. This would be consistent with the observation that among the five occludin sequences available, it is the unusual composition of the loop, and not necessarily its primary sequence, which is conserved (Ando-Akatsuka, cited above). Occludin has been shown to be a component of the tight junction strands visualized in by freeze fracture electron microscopy (Fujimoto, K., *J. Cell Sci.*, 108:3443-3449 (1995)). The ability to form linear polymers in the plasma membrane and interact over an extensive protein surface may be the mechanism by which occludin creates a molecular-level barrier across the paracellular pathway.

The results confirm the topography of occludin, demonstrate occludin's ability to induce adhesion when expressed in cells lacking tight junctions and suggest it must be clustered or interact with cytoplasmic proteins in order to be adhesive. Together these results suggest testable models for how the occludin-based intercellular seal of the tight junction is created by both the specific chemistry of its extracellular loops and by influences of cytoplasmic plaque proteins.

The invention was made with partial government support with NIH R01 DK45134, NIH P01 DK38979, and NCI CA66263 grants. The government has certain rights in the invention.

The above description is for the purpose of teaching the person of ordinary skill in the art how to practice the present invention, and it is not intended to detail all those obvious modifications and variations of it which will become apparent to the skilled worker upon reading the description. It is intend-

WO 97/33605

ICT/US97/05809

- 29 -

ed, however, that all such obvious modifications and variations be included within the scope of the present invention, which is defined by the following claims. The claims are intended to cover the claimed components and steps in any sequence which is effective to meet the objectives there intended, unless the context specifically indicates the contrary.

The papers cited above are expressly incorporated herein in their entireties by reference.

WO 97/33605

PCT/US97/05809

- 30 -

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANTS: James M. Anderson
Christina M. Van Itallie
- (ii) TITLE OF INVENTION: Human Occludin, Its Uses
and Enhancement of Drug Absorption Using Occludin Inhibitors
- (iii) NUMBER OF SEQUENCES: 6
- (iv) CORRESPONDENCE ADDRESS
 - (A) ADDRESSEE: Yale University Medical School
Section of Digestive Diseases
Department of Internal Medicine
 - (B) STREET: 333 Cedar Street, LCI 105
 - (C) CITY: New Haven
 - (D) STATE: Connecticut
 - (E) COUNTRY: United States of America
 - (F) ZIP CODE: 06520-8057
- (v) COMPUTER READABLE FORM
 - (A) MEDIUM TYPE: 3.5" 1.44 Mb diskette
 - (B) COMPUTER: IBM PC
 - (C) OPERATING SYSTEM: MS DOS
 - (D) SOFTWARE: Word Processing
- (vi) CURRENT APPLICATION DATA
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE: March 14, 1997
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA
 - (A) APPLICATION NUMBER: U.S. 60/013,625
 - (B) FILING DATE: March 15, 1996
 - (C) CLASSIFICATION:
- (viii) ATTORNEY INFORMATION
 - (A) NAME: Mary M. Krinsky
 - (B) REGISTRATION NO.: 32423
 - (C) REFERENCE/DOCKET NUMBER: 1751-P0016B.PCT
- (ix) TELECOMMUNICATION INFORMATION
 - (A) TELEPHONE NUMBER: 203-324-6155
 - (B) TELEFAX NUMBER: 203-327-1096

WO 97/33605

PCT/US97/05809

- 31 -

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2312

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE:

(A) DESCRIPTION: cDNA

(v) FRAGMENT TYPE: complete sequence

(ix) FEATURE:

(A) NAME/KEY: human occludin

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

```

GCCTCTCTCC ATCAGACACC CCAAGGTTC ATCCGAAGCA GGCGGAGCAC 50
CGAACGCACC CCGGGGTGGT CAGGGACCCC CATCCGTGCT GCCCCCTAGG 100
AGCCCGCGCC TCTCCTCTGG GCCCGCCTC TCGGGCCGCA ACATCGCGCG 150
GTTCTTTTAA CAGCGCGCTG GCAGGGTGTG GGAAGCAGGA CCGCGTCCTC 200
CCGCCCCCTC CCATCCGAGT TTCAGGTGAA TTGGTCACCG AGCGAGGAGG 250
CCGACACACC ACACCTACAC TCCCGCTCC ACCTCTCCCT CCCTGCTTCC 300
TCTTGGCGGA GGCGGCAGGA ACCGAGAGCC AGGTCCAGAG CGCCGAGGAG 350
CCGGTCTAGG ACGCAGCAGA TTGGTTTATC TTGGAAGCTA AAGCGCATTG 400
GTCATCCTGA AGATCAGCTG ACCATTGACA ATCAGCCATG TCAATCCAGGC 450
GTCTTGAAAG TCCACCTCTT TACAGGCTG ATGAATTCAA ACCGAATCAT 500
TATGCACCAA GCAATGACAT ATATGGTGA GAGATGCATG TTGACCAAT 550
GCTCTCTCAG CCAGCCTACT CTTTTTACCC AGAAGATGAA ATTCTTCACT 600
TCTACAAATG GACCTCTCCT CCAGGAGTGA TTCGGATCCT GTCTATGCTC 650
ATTATTGTGA TGTGCATTGC CATCTTTGCC TGTGTGGCCT CCAACGCTTG 700
CTGGGACAGA GGCTATGGAA GTTCCCTTTT AGGAGGTAGT GTAGGCTACC 750
CTTATGGAGG AAGTGGCTTT GGTAGCTACG GAAGTGGCTA TGGCTATGGC 800
TATGGTTATG GCTATGGCTA CGGAGGCTAT ACAGACCCAA GAGCAGCAAA 850
GGGCTTCATG TTGGCCATGG CTGCCTTTTG TTTCATTGCC GCGTTGGTGA 900
TCTTTGTTAC CAGTGTTATA AGATCTGAAA TGTCCAGAAC AAGAAGATAC 950
TACTTAAGTG TGATAATAGT GAGTGCTATC CTGGGCATCA TGGTGTATTAT 1000
TGCCACAATT GTCTATATAA TGGGAGTGAA CCCAACTGCT CAGTCTTCTG 1050
GATCTCTATA TGGTTCACAA ATATATGCCC TCTGCAACCA ATTTTATACA 1100
CCTGCAGCTA CTGGACTCTA CGTGGATCAG TATTGTATC ACTACTGTGT 1150
TGTGGATCCC CAGGAGGCCA TTGCCATTGT ACTGGGGTTC ATGATTATTG 1200

```

WO 97/33685

PC17US97/05809

- 32 -

TGGCTTTTGC TTTAATAATT TTCTTTGCTG TGAAAACTCG AAGAAAGATG 1250
 GACAGGTATG ACAAGTCCAA TATTTTGTGG GACAAGGAAC ACATTTATGA 1300
 TGAGCAGCCC CCCAATGTCG AGGAGTGGGT TAAAAATGTG TCTGCAGGCA 1350
 CACAGGACGT GCCTTCACCC CCATCTGACT ATGTGGAAAG AGTTGACAGT 1400
 CCCATGGCAT ACTCTTCCAA TGGCAAAGTG AATGACAAGC GGTTTTATCC 1450
 AGAGTCTTCC TATAAATCCA CGCCGGTTCC TGAAGTGGTT CAGGAGCTTC 1500
 CATTAACTTC GCCTGTGGAT GACTTCAGGC AGCCTCGTTA CAGCAGCGGT 1550
 GGTAACTTTG AGACACCTTC AAAAAGAGCA CCTGCAAAGG GAAGAGCAGG 1600
 AAGGTCAAAG AGAACAGAGC AAGATCACTA TGAGACAGAC TACAACACTG 1650
 GCGGCGAGTC CTGTGATGAG CTGGAGGAGG ACTGGATCAG GGAAATATCCA 1700
 CCTATCACTT CAGATCAACA AAGACAACCTG TACAAGAGGA ATTTTGACAC 1750
 TGGCCTACAG GAATACAAGA GCTTACAATC AGAAGCTGAT GAGATCAATA 1800
 AAGAACTCTC CCGTTTGGAT AAAGAATTGG ATGACTATAG AGAAGAAAGT 1850
 GAAGAGTACA TGGCTGCTGC TGATGAATAC AATAGACTGA AGCAAGTGAA 1900
 GGGATCTGCA GATTACAAA GTAAGAAGAA TCATTGCAAG CAGTTAAAGA 1950
 GCAAATTGTC ACACATCAAG AAGATGGTTG GAGACTATGA TAGACAGAAA 2000
 ACATAGAAGG CTGATGCCAA GTTGTGTTGAG AAATTAAAGTA TCTGACATCT 2050
 CTGCAATCTT CTCAGAAGGC AAATGACTTT GGACCATAAC CCCGGAAGCC 2100
 AAACCTCTGT GAGCATCACA AAGTTTTGGG TTGCTTTAAC ATCATCAGTA 2150
 TTGAAGCATT TTATAAATCG CTTTGTGATAA TCAACTGGGC TGAACAACCTC 2200
 CAATTAAGGA TTTTATGCTT TAAACATTGG TTCTTGTAAT AAGAATGAAA 2250
 TACTGTTTGA GGTTTTTAAG CCTTAAAGGA AGGTTCTGGT GTCAACTAAA 2300
 CTTTCACACC CC 2312

(3) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 522

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE:

(A) DESCRIPTION: polypeptide

(v) FRAGMENT TYPE: complete sequence

(ix) FEATURE:

(A) NAME/KEY: human occludin

WO 97/33605

PCT/US97/05809

- 33 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met	Ser	Ser	Arg	Pro	Leu	Glu	Ser	Pro	Pro	Pro	Tyr	Arg	Pro	Asp	5	10	15
Glu	Phe	Lys	Pro	Asn	His	Tyr	Ala	Pro	Ser	Asn	Asp	Ile	Tyr	Gly	20	25	30
Gly	Glu	Met	His	Val	Arg	Pro	Met	Leu	Ser	Gln	Pro	Ala	Tyr	Ser	35	40	45
Phe	Tyr	Pro	Glu	Asp	Glu	Ile	Leu	His	Phe	Tyr	Lys	Trp	Thr	Ser	50	55	60
Pro	Pro	Gly	Val	Ile	Arg	Ile	Leu	Ser	Met	Leu	Ile	Ile	Val	Met	65	70	75
Cys	Ile	Ala	Ile	Phe	Ala	Cys	Val	Ala	Ser	Thr	Leu	Ala	Trp	Asp	80	85	90
Arg	Gly	Tyr	Gly	Thr	Ser	Leu	Leu	Gly	Gly	Ser	Val	Gly	Tyr	Pro	95	100	105
Tyr	Gly	Gly	Ser	Gly	Phe	Gly	Ser	Tyr	Gly	Ser	Gly	Tyr	Gly	Tyr	110	115	120
Gly	Tyr	Gly	Tyr	Gly	Tyr	Gly	Tyr	Gly	Gly	Tyr	Thr	Asp	Pro	Arg	125	130	135
Ala	Ala	Lys	Gly	Phe	Met	Leu	Ala	Met	Ala	Ala	Phe	Cys	Phe	Ile	140	145	150
Ala	Ala	Leu	Val	Ile	Phe	Val	Thr	Ser	Val	Ile	Arg	Ser	Glu	Met	155	160	165
Ser	Arg	Thr	Arg	Arg	Tyr	Tyr	Leu	Ser	Val	Ile	Ile	Val	Ser	Ala	170	175	180
Ile	Leu	Gly	Ile	Met	Val	Phe	Ile	Ala	Thr	Ile	Val	Tyr	Ile	Met	185	190	195
Gly	Val	Asn	Pro	Thr	Ala	Gln	Ser	Ser	Gly	Ser	Leu	Tyr	Gly	Ser	200	205	210
Gln	Ile	Tyr	Ala	Leu	Cys	Asn	Gln	Phe	Tyr	Thr	Pro	Ala	Ala	Thr	215	220	225
Gly	Leu	Tyr	Val	Asp	Gln	Tyr	Leu	Tyr	His	Tyr	Cys	Val	Val	Asp	230	235	240
Pro	Gln	Glu	Ala	Ile	Ala	Ile	Val	Leu	Gly	Phe	Met	Ile	Ile	Val	245	250	255

WO 97/33605

PCI/US97/05809

- 34 -

Ala Phe Ala Leu	Ile Ile Phe Phe Ala	Val Lys Thr Arg Arg Lys	260	265	270
Met Asp Arg Tyr	Asp Lys Ser Asn Ile	Leu Trp Asp Lys Glu His	275	280	285
Ile Tyr Asp Glu	Gln Pro Pro Asn Val	Glu Glu Trp Val Lys Asn	290	295	300
Val Ser Ala Gly	Thr Gln Asp Val Pro	Ser Pro Pro Ser Asp Tyr	305	310	315
Val Glu Arg Val	Asp Ser Pro Met Ala	Tyr Ser Ser Asn Gly Lys	320	325	330
Val Asn Asp Lys	Arg Phe Tyr Pro Glu	Ser Ser Tyr Lys Ser Thr	335	340	345
Pro Val Pro Glu	Val Val Gln Glu Leu	Pro Leu Thr Ser Pro Val	350	355	360
Asp Asp Phe Arg	Gln Pro Arg Tyr Ser	Ser Gly Gly Asn Phe Glu	365	370	375
Thr Pro Ser Lys	Arg Ala Pro Ala Lys	Gly Arg Ala Gly Arg Ser	380	385	390
Lys Arg Thr Glu	Gln Asp His Tyr Glu	Thr Asp Tyr Thr Thr Gly	395	400	405
Gly Glu Ser Cys	Asp Glu Leu Glu Glu	Asp Trp Ile Arg Glu Tyr	410	415	420
Pro Pro Ile Thr	Ser Asp Gln Gln Arg	Gln Leu Tyr Lys Arg Asn	425	430	435
Phe Asp Thr Gly	Leu Gln Glu Tyr Lys	Ser Leu Gln Ser Glu Leu	440	445	450
Asp Glu Ile Asn	Lys Glu Leu Ser Arg	Leu Asp Lys Glu Leu Asp	455	460	465
Asp Tyr Arg Glu	Glu Ser Glu Glu Tyr	Met Ala Ala Ala Asp Glu	470	475	480
Tyr Asn Arg Leu	Lys Gln Val Lys Gly	Ser Ala Asp Tyr Lys Ser	485	490	495
Lys Lys Asn His	Cys Lys Gln Leu Lys	Ser Lys Leu Ser His Ile	500	505	510
Lys Lys Met Val	Gly Asp Tyr Asp Arg	Gln Lys Thr	515	520	

WO 97/33605

PCT/US97/05809

- 35 -

(4) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE:

- (A) DESCRIPTION: peptide

(v) FRAGMENT TYPE: synthetic peptide

(ix) FEATURE:

- (D) OTHER INFORMATION: construct used in experiments

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Cys Asp Arg Gly Tyr Gly Thr Ser Leu Leu Gly Gly Ser Val Gly
5 10 15
Tyr Pro Tyr Gly Gly Ser Gly Phe Gly
20

(5) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE:

- (A) DESCRIPTION: peptide

(v) FRAGMENT TYPE: synthetic peptide

(ix) FEATURE:

- (D) OTHER INFORMATION: construct used in experiments

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Cys Ser Tyr Gly Ser Gly Tyr Gly Tyr Gly Tyr Gly Tyr Gly Tyr
5 10 15

WO 97/33605

PC10/US97/05809

- 36 -

Gly Tyr Gly Gly Tyr Thr Asp Pro Arg
20

(6) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE:

- (A) DESCRIPTION: peptide

(v) FRAGMENT TYPE: synthetic peptide

(ix) FEATURE:

- (D) OTHER INFORMATION: construct used in experiments

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Asn His Tyr Ala Pro Ser Asn Asp Ile Tyr Gly Gly Glu Met Val
5 10 15
His Arg Pro Met Leu
20

(7) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE:

- (A) DESCRIPTION: peptide

(v) FRAGMENT TYPE: synthetic peptide

(ix) FEATURE:

- (D) OTHER INFORMATION: construct used in experiments

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Ala Ser Gln Gln Val Tyr Arg Lys Asp Pro Cys
5 10

WO 97/33605

PCT/US97/05809

- 37 -

CLAIMS

1. An isolated and purified human occludin polypeptide shown in SEQ ID NO: 2, or a fragment or variant thereof.
2. A polypeptide according to claim 1 corresponding to residues 90 to 138 of SEQ ID NO:2, or a fragment or variant thereof.
3. A polypeptide according to claim 1 corresponding to residues 196 to 246 of SEQ ID NO: 2, or a fragment or variant thereof.
4. An isolated nucleic acid molecule comprising a sequence selected from the group consisting of:
 - (a) a sequence of a genomic DNA clone or a cDNA encoding human occludin, wherein the noncoding strand of said DNA hybridizes under stringent conditions with a DNA probe having the sequence shown as nucleotides 534 to 2003 of SEQ ID NO:1;
 - (b) a sequence degenerate with the sequence of (a); and
 - (c) a sequence complementary to the full length of the nucleic acid of (a) or (b).
5. A nucleic acid molecule according to claim 4 which is DNA.
6. A nucleic acid molecule according to claim 4 which is RNA.
7. A nucleic acid molecule according to claim 4 which encodes human occludin.
8. A method for enhancing drug delivery in a patient comprising administering an effective amount of an occludin inhibitor to said patient.

WO 97/33605

PCT/US97/05809

- 38 -

9. A method according to claim 8 wherein the occludin inhibitor is a peptide having a sequence corresponding to residues 90 to 138 of SEQ ID NO: 2, or a fragment or variant thereof.

10. A method according to claim 8 wherein the occludin inhibitor is a peptide having a sequence corresponding to residues 196 to 246 of SEQ ID NO: 2, or a fragment or variant thereof.

11. A method for screening for an occludin inhibitor comprising assaying for binding to a sequence selected from the group consisting of residues 90 to 138 of SEQ ID NO: 2, a sequence corresponding to residues 196 to 246 of SEQ ID NO: 2, fragments thereof, variants thereof, and mixtures of any of these.

12. A method according to claim 11 comprising an *in vitro* binding assay.

13. A method according to claim 11 comprising an *in vitro* assay measuring adhesive properties of the sequences.

14. A method according to claim 13 which comprises fibroblast adhesion measurements.

15. A method according to claim 14 which comprises electrical resistance measurements or transmonolayer flux measurements.

16. A method for screening for the presence or absence of occludin inhibition by a test sample comprising:

(a) adding the test sample to an *in vitro* culture of epithelial or endothelial cells;

5 (b) adding an occludin loop peptide and the test sample to a second culture of the same cells;

WO 97/33605

PCT/US97/05809

- 39 -

(c) incubating the cultures for such time under such conditions sufficient to observe growth in cultures containing no test sample;

(d) comparing the extent of adhesion in cultures with test sample and peptide with the extent of adhesion in cultures with no peptide; and

(e) determining the presence of inhibition by observation of more adhesion in cultures with test sample and less adhesion in cultures having test sample and peptide.

17. A method for screening for the presence or absence of occludin inhibition by a test sample comprising:

(a) adding the test sample to an *in vitro* culture of epithelial or endothelial cells;

(b) adding an occludin loop peptide and the test sample to a second culture of the same cells;

(c) adding a tracer compound to both cultures;

(d) incubating the cultures for such time under such conditions sufficient to observe growth in cultures containing no test sample;

(e) comparing the extent of tracer uptake in cultures with test sample and peptide with the extent of tracer uptake in cultures with no peptide; and

(f) determining the presence of inhibition by observation of increased tracer uptake in cultures with test sample and decreased tracer uptake in cultures having test sample and peptide.

18. A method according to claims 16 or 17 wherein the occludin loop peptide corresponds to residues 90 to 138 of SEQ ID NO:2, or a fragment or variant thereof.

19. A method according to claims 16 or 17 wherein the occludin loop peptide corresponds to residues 196 to 246 of SEQ ID NO: 2, or a fragment or variant thereof.

20. An occludin inhibitor identified according to the methods of claims 11 to 16.

WO 97/33605

PCT/US97/05809

1/6

Figure 1

ATTGAAATCAAATTTCTCAGCTTTAGATATTTATAAACAGTACACATGAGTCTTATTA
----- 60
TAACCTTAGTTTAAGAGTGCAGAAATCTATAAATATTTTGTCTATGTGTACTCAGAAATAT

CAACTCTACAGGTGCGAAAACATGTATTCTAATCTAATCATATGCACCAAGCAATGACA
----- 120
CTTGAGATGTGCAGCTTTTGTACATAAGATTAGATTAGTATTACGTGGTTCTGTACTGT

TATATGCTGGAGAGATGCAATGTTTCGACCAATGCTCTCTCAGCCAGCCTACTCTTTTACC
----- 180
ATATACCACCTCTCTACSTACAGCTGTTTACGAGAGAGTCCGTCCGATCTGAAAAATGG

M N V R P M L S Q P A Y H F Y D .

CAGAAGATGAAATTTCTTCACTTCTACAAATGGACCTCTCTCCAGGAGTATTCGGATCC
----- 240
GTCTCTACTTTAAGAAGTGAAGATGTTTACCTGGAGAGAGAGTCTCTCATTAGCCTAGG

E D E I L H F Y X W T E D P G V I R I L .

TGTCTATGCTCATTATTGTGATGTGCATTCGCATCTTTCCTGTGTGGCTCCAGCGTTG
----- 300
ACAGATACGAGTAATAACACTACAGCTAACGGTAGAAACGACACACCGTAGGTCCGAAC

S M L I I V M C I A E A C V A S T L A .

CCTGGACAGAGCTATGGAATTCCTTTTAGGAGGTAGTGTAGCTACCTTATGGAG
----- 360
CGACCTGTCTCCGATACCTTCAAGCGAAATGCTCCATCAGTCCGATCGGAATACCTC

H D R G Y G T E L L G G S V G G Y D V G G C .

GAAATGGCTTTGGTAGCTACGGAAGTGGCTATGGCTATGGCTATGGTTTGGCTATGGCT
----- 420
CTTCACGAAACCATCGATGCCTTCACCGATACCGATACCGATACCAATTCGGATACCGA

S G F G S Y G S G Y G Y G Y G Y G Y .

ACGGAGCTATACAGACCCAGAGAGCAGCAAGGGCTTCTGTTGGCAATGGCTGCTTTT
----- 480
TGCTCCGATATGCTGGGTTCTGCTGTTTCCGAGTACAACCGGTTCGACGGAATA

G O Y T D P R A A K G F M L A H A A F C .

SUBSTITUTE SHEET (RULE 26)

WO 97/33605

PCT/US97/05809

2/6

GTTCATTGCCCGCTTGGTGATCTTTGTTACCACTGTTTATAAGATCTGAATGTCAGAA
181 ----- 540
CAAAGTAACGGCGCCACCCTAGAAACAATGGTCACAATATTCTAGAGTTTACAGGCTCT
P I A A L V I F V T S V I R S E M S R T -
CAAGAAGATACTACTTAAGTGTGATAATAGTGAGTGCTATCTGGGCATCATGGTGTITA
541 ----- 600
GTTCTTCTATGATGAATTCACACTATTATCACTCAGGATAGGACCCOTAGTACCACAAAT
R R Y Y L S V I I V S A I T L G I M V F : -
TTGCCACAATTGCTATATAATGGGAGTGAACCCAACTGCTCAGTCTTCTGGATCTCTAT
601 ----- 660
AACGGTGTAAACAGATATATTACCCTCACTTGGGTTGACGAGTCAGAGACCTAGAGATA
A T I V Y I M G V N P T A Q S S G S L Y -
ATGTTTCACAATATATGCGCTCTGCAACCAATTTTATACAGCTGCAAGTACTGGAAGTCT
661 ----- 720
TACCAAGTGTATATACGGGAGACGTTGGTTAAATATGTGGACGTCGATGCTCTGAGA
G S Q I Y A L C N Q E Y T P A A T G L Y -
ACGTGGATCAGTATTTGTATCACTACTGTGTTGTGGATCCCCAGGAGGCCATTTGCCATTG
721 ----- 780
TGCACCTAGTCATAACATAGTGATGACACAACACCTAGGGGTCTCCGGTJJCAGTAAC
V D Q Y L Y H Y C V V D P Q E A E A I V -
TACTGGGTTGATGATTATTGTGCTTTTCTTTAATAATTTTCTTTGCTGTAAAACTC
781 ----- 840
ATGACCCCAAGTACTAATAACACCGAAAACGAAATTATTAAAGAAACGACATTTTGAAG
L O P M I I V A F A L I I F F A V K T R -
GAAGAAAGATGGACAGGTATGACAAGTCCATATTTTGTGGGACAAAGAACTCATTTATG
841 ----- 900
CTTCTTTCTACCTGTCCATACTGTTTCAAGTTATAAAACACCCGTGCTCTGTGTAAATAC
R K M D R Y D K S N I L W D K E H T Y D -
ATGAGCAGCCCCCAATGTGAGGAGTGGGTTAAAAATGTGTCTCAGGCCATTCAGGACG
901 ----- 960
TACTCOTCGGGGGGTTACAGCTCCTCACCCAAATTTTACACAGACGTCGGTGTCTCTGC
E Q P P N V E E W V K N V S A G T Q D V -
TGCCTTCACCCCCATCTGACTATGTGGAAGAGTTGACAGTCCCATGGCATTTCTTCCA
961 ----- 1020
ACGGAAGTGGGGGTAGACTGATACACCTTTCTCACTGTCAAGGTACCGTANAGAAAGGT
P S P P S D Y V E R V D S P M A Y S S N -

SUBSTITUTE SHEET (RULE 26)

PCT/US97/05809

ATECCAAAGTGAATGACACAGCGGTTTATCCAGAGTCTTCTATAAATCCAGGCCGGTTC

G K V N D K R F Y P E S S Y X S T P V P -

CTGAAGTGGTT CAGGAGCTT CCATTAACTTGGCCTGTGGATGACTTCAGGCNCCCTCGT.

E V V Q E L P L T S P V D D F R Q P R Y -

ACAGCAGCGGTGGTAACTTTGAGACACCTTCAAAAAGAGCACCTGCAAGGTAAGAGCAG

S S G G N F E T P S K R A P A X G R A G .

GAAGGTCAGAGAACAGAGCAAGATCACTATGAGACAGACTACACAAGTTCGGCGAGT

R S K R T E Q D N Y E T D Y T T G G E S -

CCTGTGATGAGCTGGAGGAGGACTGGATCAGCGAATATCCACTATCACTTCAGATCAAC

C D E L E S D W I R E Y P P I T S D Q Q -

AAAGAGAACTGTACAAQAGGAATTTGACACTGGCCTACAGGAATACAAGCTTACAAAT

..H Q L Y K R N F D T G L Q X Y K S L Q S -

CAGAACTTGATGAGATCAATAAGAACTCTCCGTTTGGATAAAGAAATTGGCTGACTATA

E L D E T N K E L S R L D K E L D D Y R.

GGAGAGAAAGTGAAGAGTACATGGCTGCTGCTGATGAATACATAGACTGJJGCAAGTGA

E E S E R Y M A A A D E Y N R L R Q V X -

AGGGATCTGCAGATTACAAAGTAAGAGAAATCATTGCAAGCAGTTAAACAGACAAATTGT

G S A D Y K G K K N H C K Q L N S K L S -

Received from < 1 206 682 6031 > at 5/1/02 3:13:21 PM [Eastern Daylight Time]

WO 97/33605

PCT/US97/05809

4/6

CACACATCAAGAAGATGGTTGGAGACTATGATAGACAGAAAACATAGAGGCTGATGCCA
1561 ----- 1620
GTGTGTAGTTCTTCTACCAACCTCTGATACTATCTGTCTTTGTATCTCCGACACGGT

H I X K M V G D Y D R Q K T *

AGTTGTTTGAGAAATTAGTATCTGACATCTCTGCAATCTTCTCAGAAGGCCAAATCACTT
1621 ----- 1680
TCAACAAACTCTTTAATTCATAGACTGTAGAGACGTTAGAGAGTCTTCCGTTTACTGAA

TGGACCATAACCCCGGAAGCCAAACCTCTGTGAGCATCACAAAGTTTTGGGTTGCTTTAA
1681 ----- 1740
ACCTGGTATTGGGGCCTTCGGTTTGGAGACTCGTAGTGTTCAAAACCCAACGAAATT

CATCATCAGTATTGAAGCAATTTATAAATCCCTTTTGATAATCAACTGGGCTGAACCACT
1741 ----- 1800
GTAGTAGTCATAACTTCGTAAATATTTAGCCAAAACATTAGTTGACCCGACTTGTGA

CCAATTAAGGATTTTATGCTTTAAACATTGGTCTTGTATTAGAATGAATACGTGTTG
1801 ----- 1860
GGTTAATTCCTAAATACGAATTTGTAAACCAAGAACATAATCTTACTTTATGCAAAAC

AGGTTTAAAGCCTTAAGCAAGGTTCTGTTGTGAACATAACTTTCACACCCC
1861 ----- 1923
TCCAAAAATTCGAATTTCTTCCAAACACCACTGATTTCGAAGTGTGGGG

SUBSTITUTE SHEET (RULE 26)

WO 97/33605

PCT/US97/05809

5/6





Figure 2





Figures 3A-3C

SUBSTITUTE SHEET (RULE 26)

WO 97/33605

PCT/US97/05809

6/6

**Figure 4****Figures 5A-5C**

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/05309

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 38/16, 38/17; C07H 21/04; C12Q 1/08

US CL : 435/40.51; 514/8; 530/353; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/40.51; 514/8; 530/353; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG, MEDLINE, EMBASE, BIOSIS, LIFESCI, WPID

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	FURUSE et al. Occludin: A Novel Integral Membrane Protein Localizing at Tight Junctions. J. Cell Biology. 15 December 1993, Vol. 123, No. 6, Part 2, pages 1777-1788, see entire document.	1-20
Y, P	ANDO-AKATSUKA et al. Interspecies Diversity of the Occludin Sequence: cDNA Cloning of Human, Mouse, Dog, and Rat-Kangaroo Homologues. J. Cell Biology. April 1996, Vol. 133, No. 1, pages 43-47, see entire document.	1-20

☒ Further documents are listed in the Continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	T later documents published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*K* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

03 JUNE 1997

Date of mailing of the international search report

26 JUN 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PATRICK NOLAN

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/05805

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, P	WONG et al. A Synthetic Peptide Corresponding to the Extracellular Domain of Occludin Perturbs the Tight Junction Permeability Barrier. J. Cell Biology. 27 January 1997, Vol. 136, No. 2, pages 399-409, see entire document.	1-20

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*